Why Radiolabelled Human Studies Matters
A recent announcement that the testing company SGS has received approval from Belgium’s Federal Agency for Nuclear Control to resume human ADME studies using carbon-14 radiolabelled investigational products may sound obscure, even alarming, to the uninitiated. Yet for scientists and patients alike, it represents a quiet but important step forward in the development of safer and more effective medicines.
ADME stands for absorption, distribution, metabolism and excretion – the four key stages that determine what happens to a drug after it enters the human body. In simple terms, these studies answer a crucial question – once a medicine is swallowed, injected or inhaled, where does it go, what does it become, and how does it leave?
To answer that question with precision, researchers sometimes use a technique involving radiolabelling. A tiny amount of a radioactive form of carbon, known as carbon-14, is attached to the drug molecule. Because this isotope emits a detectable signal, scientists can track the medicine and its breakdown products as they move through the body.
The doses involved are extremely small – often comparable to the amount of natural background radiation a person receives over a few days. The goal is not treatment but measurement. By collecting blood, urine and sometimes breath samples, researchers can see exactly how a drug behaves in real people.
For the pharmaceutical industry, such information is indispensable. Many promising compounds fail not because they do not work, but because they accumulate in the wrong organs, produce harmful metabolites or linger in the body for too long. ADME studies help identify these problems early, long before a drug reaches the wider public.
They also make medicines safer. Regulators require detailed knowledge of how a drug is processed in the body before granting approval. Radiolabelled studies can reveal whether a compound crosses the blood–brain barrier, whether it builds up in the liver or kidneys, or whether it produces by-products that might be toxic.
In practical terms, this can shorten development timelines and reduce the number of failed late-stage trials, which are both costly and ethically troubling. A clearer understanding of a drug’s journey through the body allows researchers to design better dosing schedules, anticipate interactions with other medications, and tailor treatments to specific patient groups.
The benefits extend beyond industry economics. Faster, more reliable drug development means new treatments for cancer, rare diseases and chronic conditions can reach patients sooner. In an era when personalised medicine is gaining ground, detailed ADME data also supports the design of therapies that work more precisely for different populations.
Still, the mention of radioactivity is enough to raise eyebrows. Is there cause for concern?
Experts generally say no, provided strict regulations are followed. Carbon-14 has been used safely in human studies for decades. The radiation doses involved are typically a fraction of those used in common medical imaging procedures such as CT scans. Participants are carefully screened, informed of the risks, and monitored throughout the study.
In Europe, such research is subject to rigorous oversight from ethics committees, nuclear safety authorities and medicine regulators. The approval granted to SGS indicates that the facilities, protocols and safety measures have met these stringent standards.
That does not mean the process is casual. Radiolabelled studies are usually conducted with small groups of healthy volunteers, under tightly controlled conditions. The use of radioactive materials is justified only when the scientific value cannot be achieved through other means.
As drug discovery grows more complex, tools that reveal the hidden journeys of molecules inside the human body are becoming ever more valuable. The resumption of these studies in Belgium is unlikely to make headlines beyond scientific circles. But for the researchers tracing the path of the next generation of medicines and the patients waiting for them – it may prove quietly significant.
Photo – ©Pharmaron, 2026